Startup funding includes a Series A round led by venture capital firms Pitanga, Ecoa Capital and MOV Investimentos, along with a grant from FINEP
Following a US$ 3 million seed investment in 2022, Nintx (Next Innovative Therapeutics), a biotech company researching and developing treatments for multifactorial diseases using Brazil’s biodiversity, has just raised an additional US$ 10 million.
The investments will support the company’s plans for the coming years, which include accelerating the R&D of eight new drug programs (mostly in partnership with companies, such as Adeste and Centroflora, and research institutions, such as CIEnP and CNPEM, which houses Sirius, one of the largest particle accelerators in the world), hiring researchers, introducing new technologies, and expanding the laboratory.
Nintx employs an innovative approach to tackling multifactorial diseases caused by genetic and environmental factors as well as their interactions, especially those mediated by the human gut microbiome. The biotech focuses on multi-target therapies, leveraging proprietary technologies such as xGIbiomics®, which simulates the gastrointestinal system, and GAIApath®, a knowledge-graph data analytics platform that maps connections between plants, natural products, biological targets, the human microbiome, and multifactorial diseases.
Also Read: ZEISS & Mindpeak Enhance mIF Solutions for Pathology
Nintx’s business model involves advancing therapies to the end of preclinical studies, at which point it plans to license them to large pharmaceutical companies for clinical development and commercialization. The team anticipates that the first drug candidate will be licensed within three years.
Investors in the Series A round include venture capital firms Pitanga, Ecoa Capital and MOV Investimentos. Strategic partners Tiaraju and Adeste also invested to strengthen synergies between their businesses and Nintx. Guilherme Leal, co-founder of Natura and Dengo, and Peter Andersen, from Centroflora, remain shareholders. The Series A funds — unprecedented for a biotech startup in Brazil’s pharmaceutical sector — are complemented with a grant of US$ 2.5 million by FINEP, a public company that promotes and finances science, technology and innovation.
“In the U.S. and Europe, biopharmaceutical startups that begin licensing innovative drugs to major pharma companies can achieve valuations in the hundreds of millions of dollars. We believe Nintx has the potential to follow the same trajectory,” says Gabriel Perez from Pitanga.
“What drew our attention was Nintx’s social and environmental impact potential, as it values biodiversity through agroforestry practices, investments in small farmers, and benefit-sharing agreements with communities that hold knowledge about these plants,” says Paulo Bellotti from MOV Investimentos.
Source: Businesswire